Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Development of Nimesulide Analogues as Dual Tubulin and HSP27 Inhibitor for Treating Female Cancers

Version 1 : Received: 22 September 2020 / Approved: 22 September 2020 / Online: 22 September 2020 (15:19:02 CEST)

How to cite: Jarragh Alhadad, L.; Alanazi, F.; Harisa, G. Development of Nimesulide Analogues as Dual Tubulin and HSP27 Inhibitor for Treating Female Cancers. Preprints 2020, 2020090523 (doi: 10.20944/preprints202009.0523.v1). Jarragh Alhadad, L.; Alanazi, F.; Harisa, G. Development of Nimesulide Analogues as Dual Tubulin and HSP27 Inhibitor for Treating Female Cancers. Preprints 2020, 2020090523 (doi: 10.20944/preprints202009.0523.v1).

Abstract

Tubulin and heat shock protein 27 (HSP27) are up-regulated in cancer cells, and play a critical role in cell division, and proliferation. Therefore, they are targets for discovery of anticancer therapy. The objective of this study is to design, characterize, and biologically evaluate the nimesulide analogues to combat female cancer such as ovarian cancer, and breast cancer. Herein, the nimesulide analogues are designed to target both tubulin and HSP27 functions. Ovarian cancer (SKOV3) and breast cancer (SKBR3) cell lines were used as surrogate models to test the nimesulide analogs biological activities using MTT assay. In the present study, four nimesulide analogues were designed, synthesized and the chemical structures were with the biological evaluation were studied. The synthesized agents were characterized by 1H-NMR, 13C-NMR, the molecular weight was confirmed using GC-MS technique, and melting point. Besides, the agent L4 structure was confirmed using X-ray crystallographic analysis. The present data revealed that nimesulide analogs have potent anticancer activity against SKOV3and SKBR3 cell lines. The IC50 values for both SKOV3 and SKBR3 cell lines treated with the agents showed a potent cell growth inhibition range of 0.23-2.02 µM and 0.50-3.73 µM respectively. In conclusion, the designed nimesulide analogues can target both tubulins, and HSP27 concurrently, and they are promising agents as future chemotherapy female cancers.

Subject Areas

Anticancer; Tubulin; HSP27; Nimesulide; SKOV3; SKBR3

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.